My Breakthrough
18 JANUARY 2008
Triple Negative Trial launched
Two of the UK’s leading cancer charities, Breakthrough Breast Cancer and Cancer Research UK, today launched the first UK-based clinical trial for women with an aggressive form of breast cancer which has spread to another part of the body.
The Triple Negative Trial aims to improve breast cancer treatment for women with hormone and HER2 negative tumours, sometimes referred to as “triple negative” because they lack hormone (oestrogen and progesterone) and HER2 receptors.
Hormone and HER2 negative tumours do not respond to targeted treatments like Herceptin or hormone therapies such as tamoxifen and because of this, can be hard to treat. The Breakthrough Breast Cancer and Cancer Research UK Triple Negative Trial aims to develop a more tailored and effective chemotherapy treatment for women with hormone and HER2 negative breast cancer, which has spread elsewhere in the body.
Find out more information on triple negative breast cancer.
Find out more about the Triple Negative trial.
The Triple Negative Trial aims to improve breast cancer treatment for women with hormone and HER2 negative tumours, sometimes referred to as “triple negative” because they lack hormone (oestrogen and progesterone) and HER2 receptors.
Hormone and HER2 negative tumours do not respond to targeted treatments like Herceptin or hormone therapies such as tamoxifen and because of this, can be hard to treat. The Breakthrough Breast Cancer and Cancer Research UK Triple Negative Trial aims to develop a more tailored and effective chemotherapy treatment for women with hormone and HER2 negative breast cancer, which has spread elsewhere in the body.
Find out more information on triple negative breast cancer.
Find out more about the Triple Negative trial.
